Everlywell offers Clairity's FDA-authorized AI breast cancer risk assessment nationwide

Oct 1, 2026 · Issue 9 · 4 sources, 4 articles

Everlywell is making Clairity's FDA-authorized AI-based breast cancer risk assessment available nationwide in the United States. The announcement was published on October 1.

Who is affected and how

doctor

Patients may come with the result before a mammography screening decision, so physicians need to know the tool's limitations.

medtech company

The distribution partnership offers a model for taking authorized AI tools to the consumer channel.

Sources

• Everlywell Brings Clairity’s FDA-Authorized AI Breast Cancer Risk Assessment to Women Nationwidebusiness wire · Oct 1, 2026
• Clairity expands access to AI breast cancer risk tool via Everlywellauntminnie · Oct 1, 2026
• Everlywell rolls out Clairity AI for breast cancer in US - pharmaphorumpharmaphorum.com · Oct 2, 2026
• Everlywell rolls out Clairity AI for breast cancer in USpharmaphorum · Oct 2, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.